{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T01:53:08Z","timestamp":1772070788329,"version":"3.50.1"},"reference-count":29,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,6,1]]},"DOI":"10.2169\/internalmedicine.6233-20","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T22:20:26Z","timestamp":1610058026000},"page":"1737-1742","source":"Crossref","is-referenced-by-count":3,"title":["Vancomycin Intoxication and Cefepime-induced Encephalopathy Treated by Abdominal Drainage of Massive Ascites in Addition to Online Hemodiafiltration"],"prefix":"10.2169","volume":"60","author":[{"given":"Tomoki","family":"Taniguchi","sequence":"first","affiliation":[{"name":"Department of Nephrology, Kyoto City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kyoto City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Itoh","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kyoto City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayumi","family":"Tomita","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kyoto City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Kamata","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kyoto City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Iehara","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kyoto City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Munar MY, Singh H. Drug dosing adjustments in patients with chronic kidney disease. Am Fam Physician 75: 1487-1496, 2007."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. B\u00fcdingen FV, Gonzalez D, Tucker AN, et al. Relevance of liver failure for anti-infective agents: from pharmacokinetic alterations to dosage adjustments. Ther Adv Infect Dis 2: 17-42, 2014.","DOI":"10.1177\/2049936113519089"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Grill MF, Maganti RK. Neurotoxic effects associated with antibiotic use: management considerations. Br J Clin Pharmacol 72: 381-393, 2011.","DOI":"10.1111\/j.1365-2125.2011.03991.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Alvarez FG, Guntupalli KK. Isoniazid overdose: four case reports and review of the literature. Intensive Care Med 21: 641-644, 1995.","DOI":"10.1007\/BF01711541"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Zaric RZ, Milovanovic J, Rosic N, et al. Pharmacokinetics of vancomycin in patients with different renal function levels. Open Med 13: 512-519, 2018.","DOI":"10.1515\/med-2018-0068"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Okamoto MP, Nakahiro RK, Chin A, et al. Cefepime clinical pharmacokinetics. Clin Pharmacokinet 25: 88-102, 1993.","DOI":"10.2165\/00003088-199325020-00002"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kovarik JM, Ter Maaten JC, Rademaker CM, et al. Pharmacokinetics of cefepime in patients with respiratory tract infections. Antimicrob Agents Chemother 34: 1885-1888, 1990.","DOI":"10.1128\/AAC.34.10.1885"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Blevins RD, Halstenson CE, Salem NG, et al. Pharmacokinetics of vancomycin in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 25: 603-606, 1984.","DOI":"10.1128\/AAC.25.5.603"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ikawa K, Morikawa N, Hayato S, et al. Pharmacokinetic and pharmacodynamic profiling of cefepime in plasma and peritoneal fluid of abdominal surgery patients. Int J Antimicrob Agents 30: 270-273, 2007.","DOI":"10.1016\/j.ijantimicag.2007.04.012"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Higuchi K, Ikawa K, Ikeda K, et al. Peritoneal pharmacokinetics of cefepime in laparotomy patients with inflammatory bowel disease, and dosage considerations for surgical intra-abdominal infections based on pharmacodynamic assessment. J Infect Chemother 14: 110-116, 2008.","DOI":"10.1007\/s10156-007-0584-x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Magera BE, Arroyo JC, Rosansky SJ, et al. Vancomycin pharmacokinetics in patients with peritonitis on peritoneal dialysis. Antimicrob Agents Chemother 23: 710-714, 1983.","DOI":"10.1128\/AAC.23.5.710"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Jindal A, Kumar M, Bhadoria AS, et al. A Randomized Open Label Study of 'Imipenem vs. Cefepime' in Spontaneous Bacterial Peritonitis. Liver Int 36: 677-687, 2016.","DOI":"10.1111\/liv.12985"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Mirrakhimov AE, Barbaryan A, Gray A, et al. The role of renal replacement therapy in the management of pharmacologic poisonings. Int J Nephrol 2016: 3047329, 2016.","DOI":"10.1155\/2016\/3047329"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. MacVane SH, Housman ST, Nicolau DP. In vitro microdialysis membrane efficiency of broad-spectrum antibiotics in combination and alone. Clin Pharmacol 6: 97-101, 2014.","DOI":"10.2147\/CPAA.S65389"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Sombolos KI, Fragidis SK, Bamichas GI, et al. Subtherapeutic serum vancomycin concentrations during on-line hemodiafiltration. ASAIO J 57: 507-510, 2011.","DOI":"10.1097\/MAT.0b013e3182306196"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Appa AA, Jain R, Rakita RM, et al. Characterizing cefepime neurotoxicity: a systematic review. Open Forum Infect Dis 4: ofx170, 2017.","DOI":"10.1093\/ofid\/ofx170"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Payne LE, Gagnon DJ, Riker RR, et al. Cefepime-induced neurotoxicity: a systematic review. Crit Care 21: 276, 2017.","DOI":"10.1186\/s13054-017-1856-1"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Wanchoo R, Abudayyeh A, Doshi M, et al. Renal toxicities of novel agents used for treatment of multiple myeloma. Clin J Am Soc Nephrol 12: 176-189, 2017.","DOI":"10.2215\/CJN.06100616"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372: 142-152, 2015.","DOI":"10.1056\/NEJMoa1411321"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Mateos MV. Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev 36: S24-S32, 2010.","DOI":"10.1016\/S0305-7372(10)70009-8"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Mushtaq A, Kapoor V, Latif A, et al. Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: a systematic review. Crit Rev Oncol Hematol 125: 1-11, 2018.","DOI":"10.1016\/j.critrevonc.2018.02.008"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Bringhen S, Wit ED, Dimopoulos MA. New agents in multiple myeloma: an examination of safety profiles. Clin Lymphoma Myeloma Leuk 17: 391-407, 2017.","DOI":"10.1016\/j.clml.2017.05.003"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in north america. N Engl J Med 357: 2133-2142, 2007.","DOI":"10.1056\/NEJMoa070596"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357: 2123-2132, 2007.","DOI":"10.1056\/NEJMoa070594"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Merz M, Dechow T, Scheytt M, et al. The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma. Ann Hematol 99: 1709-1725, 2020.","DOI":"10.1007\/s00277-020-04023-4"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Wang Y, Yang F, Shen Y, et al. Maintenance therapy with immunomodulatory drugs in multiple myeloma: a meta-analysis and systematic review. J Natl Cancer Inst 108: djv342, 2015.","DOI":"10.1093\/jnci\/djv342"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Schoenbeck KL, Wildes TM. Updated perspectives on the management of multiple myeloma in older patients: focus on lenalidomide. Clin Interv Aging 15: 619-633, 2020.","DOI":"10.2147\/CIA.S196087"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Tannemaat MR, Vries EP, Molendijk WJ. Fatal ischemic stroke in a patient receiving lenalidomide for multiple myeloma. Clin Neurol Neurosurg 113: 488-489, 2011.","DOI":"10.1016\/j.clineuro.2011.01.003"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Anderson S, Kiernan M, Ho PJ. Lenalidomide-related progressive multifocal leukoencephalopathy: a case report and review of drug-related cases in multiple myeloma. Clin Lymphoma Myeloma Leuk 19: e169-e171, 2019.","DOI":"10.1016\/j.clml.2018.12.021"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/11\/60_6233-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T23:21:32Z","timestamp":1670714492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/11\/60_6233-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6233-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,1]]}}}